Food and Drug Administration (2023) Accelerated approval program. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program. Accessed 2 Feb 2024

European Medicines Agency (2006) Commission Regulation (EC) No 507/2006 of 29 March 2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council (Text with EEA relevance). In: (EMA) EMA, ed

(EMA) EMA (2022) Conditional marketing authorization. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjUuJ-9vYP9AhVAiGMGHfI7BrAQFnoECBMQAQ&url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fhuman-regulatory%2Fmarketing-authorisation%2Fconditional-marketing-authorisation&usg=AOvVaw1ISqJyCHT3HbeCSuoDNH7E. Accessed 02 Feb 2023

FDA.gov (2024) Accelerated Approval Program. https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program. Accessed 30 Nov 2023

Agyeman AS, Siegel JN, Leptak C (2022) Establishing a public resource for acceptable surrogate endpoints to support FDA marketing applications. Front Med 9:820990

Article  Google Scholar 

Ribeiro TB, Buss L, Wayant C, Nobre MRC (2020) Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018. PLoS One 15(7):e0236345

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naci H, Smalley KR, Kesselheim AS (2017) Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA 318(7):626–36

Article  PubMed  PubMed Central  Google Scholar 

Salcher-Konrad M, Naci H, Davis C (2020) Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States. The Milbank Quarterly 98(4):1219–56

Article  PubMed  PubMed Central  Google Scholar 

Petrou P, Pitsillidou O, Postma MJ (2022) The notion of surrogacy in health technology assessment: an insight in the processes of Germany, UK and France. J Med Econ 25(1):321–3

Article  PubMed  Google Scholar 

Schnog J-JB, Samson MJ, Gans ROB, Duits AJ (2021) An urgent call to raise the bar in oncology. Br J Cancer 125(11): 1477-85

Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A et al (2014) Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care 30(3):312–24

Article  PubMed  Google Scholar 

Schievink B, LambersHeerspink H, Leufkens H, De Zeeuw D, Hoekman J (2014) The use of surrogate endpoints in regulating medicines for cardio-renal disease: opinions of stakeholders. PLoS One 9(9):e108722

Article  PubMed  PubMed Central  Google Scholar 

Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS (. ;) Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. Nat Rev Drug Discov 15(7):516

Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS (2017) Time to review the role of surrogate end points in health policy: state of the art and the way forward. Value in Health 20(3):487–95

Article  PubMed  Google Scholar 

Kemp R, Prasad V (2017) Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? BMC Med 15(1):134

Article  PubMed  PubMed Central  Google Scholar 

Gyawali B, Sharma S, Booth CM (2019) Is the number of cancer drug approvals a surrogate for regulatory success? J Cancer Policy 22:100202

Article  Google Scholar 

FDA.gov. Table of surrogate endpoints that were the basis of drug approval or licensure; table of surrogate endpoints that were the basis of drug approval or licensure. FDA. Accessed 01 Feb 2024

Ciani O, Grigore B, Blommestein H, de Groot S, Möllenkamp M, Rabbe S et al (2021) Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international health technology assessment agencies. Med Decis Making: an Int J Soc Med Decision Making 41(4):439–52

Article  Google Scholar 

Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS (2014) Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA 311(4):368–77

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuster Bruce C, Brhlikova P, Heath J, McGettigan P (2019) The use of validated and nonvalidated surrogate endpoints in two European medicines agency expedited approval pathways: a cross-sectional study of products authorised 2011–2018. PLoS Med 16(9):e1002873

Article  PubMed  PubMed Central  Google Scholar 

Administration USFaD (2017) Multiple endpoints in clinical trials - guidance for industry. In: U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), ed

Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharm Therap 69(3):89–95

Article  Google Scholar 

Beakes-Read G, Neisser M, Frey P, Guarducci M (2022) Analysis of FDA’s accelerated approval program performance December 1992-December 2021. Ther Innov Regul Sci 56(5):698–703

Article  PubMed  PubMed Central  Google Scholar 

Grigore B, Ciani O, Dams F, Federici C, de Groot S, Möllenkamp M et al (2020) Surrogate endpoints in health technology assessment: an international review of methodological guidelines. PharmacoEconomics 38(10):1055–70

Article  PubMed  Google Scholar 

CIRSCI.org. CIRS RD Briefing 85 – New drug approvals in six major authorities 2012-2021; CIRS RD Briefing 85 – new drug approvals in six major authorities 2012-2021 – CIRS (cirsci.org). Accessed 01 Feb 2024

TGA.gov. Provisional determination eligibility criteria; provisional determination eligibility criteria | Therapeutic Goods Administration (TGA). Accessed 01 Feb 2024

Agency EM. Directive 2001/83/EC of the European parliament and of the council of 6 November 2001 Annex I, Part II, 6

Agency EM (2016) EMA/CHMP/509951/2006, Rev.1. Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004

EMEA/357981/2005 (2005) Guideline on procedures for the granting of a marketing authorisation under exceptional circumstances, pursuant to Article 14 (8) of regulation (EC) No 726/2004

EU. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004. 2013

Agency PaMD (2020) MHLW Notification: PSEHB/PED No. 0831/1, PSEHB/MDED No. 0831/1: handling of priority reviews, 31 August 2020

Agency PaMD (2020) MHLW notification: PSEHB/PED No. 0831/2: handling of conditional approval for pharmaceutical products

gov.UK. Conditional Marketing Authorisations, exceptional circumstances Marketing Authorisations and national scientific advice; Conditional Marketing Authorisations, exceptional circumstances Marketing Authorisations and national scientific advice - GOV.UK (www.gov.uk). Accessed 01 Feb 2024

gov.UK. Guidance for Great Britain Marketing Authorisations under exceptional circumstances; Conditional Marketing Authorisations, exceptional circumstances Marketing Authorisations and national scientific advice - GOV.UK (www.gov.uk). Accessed 01 Feb 2024

legislation.gov.UK. The human medicines regulations 2012. Conditions of UK marketing authorisation: exceptional circumstances; The Human Medicines Regulations 2012 (legislation.gov.uk). Accessed 01 Feb 2024

Aronson JK (2005) Biomarkers and surrogate endpoints. Br J Clin Pharmacol 59(5):491

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA U. The Food and Drug Modernization Act of 1997. Title 21 Code of Federal Regulations Part 314 Subpart H Section 314.500

ICH. ICH E9 statistical principles for clinical trials - Scientific guideline; ICH E9 statistical principles for clinical trials - Scientific guideline. European Medicines Agency (europa.eu)

Baker SG, Kramer BS (2015) Evaluating surrogate endpoints, prognostic markers, and predictive markers: some simple themes. Clin Trials 12(4):299–308

Article  PubMed  Google Scholar 

Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA, Group E-BMW, et al (1999) Users’ guides to the medical literature XIX Applying clinical trial results A. How to use an article measuring the effect of an intervention on surrogate end points. JAMA 282(8): 771-8

Weir CJ, Walley RJ (2006) Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 25(2):183–203

Article  PubMed  Google Scholar 

Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM et al (2014) Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol 15(3):297–304

Article  PubMed  PubMed Central  Google Scholar 

Sjoquist KM, Lord SJ, Friedlander ML, John Simes R, Marschner IC, Lee CK (2018) Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. Ther Adv Med Oncol 10:1758835918788500

Article  PubMed  PubMed Central  Google Scholar 

Tardif J-C, Heinonen T, Orloff D, Libby P (2006) Vascular biomarkers and surrogates in cardiovascular disease. Circulation 113(25):2936–42

Article  PubMed  Google Scholar 

Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA (1999) The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS (London, England) 13(7):797–804

Article  CAS  PubMed  Google Scholar 

Burzykowski T, Buyse M, Molenberghs G (2005) The evaluation of surrogate endpoints: Springer

Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys HJB (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments 1(1): 49-67

Buyse M, Sargent DJ, Grothey A, Matheson A, De Gramont A (2010) Biomarkers and surrogate end points—the challenge of statistical validation. Nat Rev Clin Oncol 7(6):309–17

Article  PubMed  Google Scholar 

Mishra P, Murray J, Birnkrant D (2015) Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: scientific and regulatory approaches to clinical trial designs. Hepatology 62(4):1298–303

Article  CAS  PubMed  Google Scholar 

Oriana C, Martin H, Toby P, Chris C, Ruth G, Claudius R et al (2013) Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. Value Health 16(6):1081–90

Article  PubMed  Google Scholar 

Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, et al (2018) Relapse-free survival as a surrogate for overall survival in the evaluation of stage II-III melanoma adjuvant therapy. J Natl Cancer Inst 110(1)

Wheaton L, Papanikos A, Thomas A, Bujkiewicz S (2023) Using Bayesian evidence synthesis methods to incorporate real-world evidence in surrogate endpoint evaluation. Med Decis Making 43(5):539–52

Article  PubMed  PubMed Central